CS Diagnostics SEC Filings

CS Diagnostics Corp. reported its Q3 2025 results. For the nine months ended September 30, 2025, revenue was $94,200 versus $106,381 a year ago, while net income improved to $32,081 from $13,448, mainly on lower operating expenses. In Q3, the company posted a small net loss of $182 on revenue of $23,050.

Total assets were $499,431,013, driven by $499.4 million of intangible assets. Cash was $13 as of September 30, 2025, with accounts payable of $1,609. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing limited liquidity and the need for additional financing.

The capital structure included 137,340,200 common shares outstanding, 10 shares of Series A preferred, 19,992,575 of Series B preferred, and 4,000,000 of Series C preferred. The company noted pending civil actions and stated internal controls over disclosure were effective as of September 30, 2025.

CS Diagnostics Corp. (CSDX) completed a capital conversion, exchanging all outstanding Series B Preferred Stock held by affiliates into an aggregate 112,652,000 Common Shares on October 30, 2025.

The exchange was conducted under Securities Act exemptions Section 3(a)(9) (existing holders; no commission paid) and, alternatively, Section 4(a)(2). The company states the move aligns capital structures ahead of consolidated financial reporting for the fiscal year ending December 31, 2025.

Following the conversion, the affiliates now hold Common Shares and remain subject to Rule 144 resale limitations, including filing, volume, manner-of-sale, and current-public-information requirements.

CS Diagnostics Corp. (CSDX) reported a quarter marked by a large intangible-asset acquisition funded by equity. The balance sheet shows $499,400,000 of intangible assets and $504,163,629 of additional paid-in capital with an accumulated deficit of $(4,735,665). Cash flows show $(345) net cash used in operating activities, $(499,444,401) used in investing largely for intangible asset purchases, and $499,444,401 provided by financing reflecting equity infusions and issuance of preferred shares. The company issued Series B preferred shares (19,992,575 outstanding) and shows common shares of 137,340,200 outstanding as of June 30, 2025. Net income for the period is noted as $196, and year-to-date changes include shares issued in connection with asset acquisition.

Antonio Santoli reports beneficial ownership of 13,596,680 shares of CS Diagnostics Corp. common stock, representing 9.9% of the class. That total includes 3,800,000 shares held directly and 9,796,680 shares issuable on conversion of Series B preferred stock, but conversion is limited by a 9.9% conversion cap in the Series B Certificate of Designation. The filing states the reported ownership excludes any additional Series B shares that cannot be converted due to that cap and excludes securities held in entities where the reporting person lacks voting or dispositive power. The filing also notes the issuer’s Preferred A shares carry supervoting rights representing over 90% of voting power, and the reporting person certifies the position is not held to change or influence control.

Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to 9.9% of the class as of the filing. The holding comprises 3,700,000 shares held directly and 9,692,434 shares issuable upon conversion of Series B preferred shares, although conversions are limited by a 9.9% cap in the Certificate of Designation. The filing states sole voting and dispositive power over the reported shares and excludes any securities held through entities where the filer lacks control. The filer certifies the stake was not acquired to change or influence control.